Product Selection Rules - Mpje

1. Which option best describes a "narrow therapeutic index" substitution concern on the MPJE?

   May require extra caution; follow state law and prescriber instructions. NTI drugs have small therapeutic windows, so substitutions demand heightened vigilance to prevent adverse outcomes per state guidelines.

2. Which Orange Book code indicates products are NOT therapeutically equivalent and should not be substituted?

   A "B"-rated code (for example, BC, BD, BX). B-rated codes denote insufficient evidence of bioequivalence, prohibiting substitution to ensure patient safety and efficacy.

3. Which option is generally required by state law after a permissible generic substitution is made?

   Notify patient and document product dispensed (varies by state). State laws typically mandate patient notification and documentation to ensure transparency and informed consent post-substitution.

4. Which option correctly states whether a pharmacist may change route (oral to topical) under generic substitution?

   No; route must match unless prescriber authorizes the change. Substitution rules require matching routes of administration to preserve intended pharmacokinetics unless explicitly authorized.

5. Which Orange Book code indicates products are therapeutically equivalent and substitutable?

   An "A"-rated code (for example, AB). A-rated codes confirm that generics meet bioequivalence standards to the reference listed drug, allowing substitution without therapeutic difference.

6. Which option best describes "pharmaceutical alternatives" in drug product selection?

   Same therapeutic moiety but different salt/ester/strength/form. Pharmaceutical alternatives vary in composition or form but provide similar therapeutic effects, often requiring prescriber approval for interchange.

7. Identify the correct action: Rx for albuterol HFA brand; generic is AB-rated and available; no DAW.

   Substitute AB-rated generic if permitted by state law. AB-rated generics are therapeutically equivalent, permitting substitution under state laws absent DAW instructions.

8. What is the dispensing implication of a prescription marked "DAW" or "brand medically necessary"?

   No generic substitution; dispense the brand as written. DAW or 'brand medically necessary' directives mandate dispensing the specified brand to honor prescriber intent and state laws.

9. Which option best describes the relationship between an authorized generic and the brand product?

   Same NDA product marketed without the brand name. Authorized generics are identical to the brand under the same NDA, allowing marketing as generics without separate approval.

10. Which option best describes "pharmaceutical equivalents" in drug product selection?

    Same active ingredient(s), dosage form, route, and strength. Pharmaceutical equivalents share identical characteristics, enabling potential therapeutic equivalence for substitution if A-rated.

11. Identify the correct action: Rx for a reference biologic; only a biosimilar (not interchangeable) is stocked.

    Do not substitute; contact prescriber for authorization. Non-interchangeable biosimilars require prescriber authorization for substitution to confirm appropriateness and safety.

12. Which option is the federal reference for biologic interchangeability and biosimilar status?

    FDA Purple Book. The FDA's Purple Book details licensed biologics and their biosimilar or interchangeable status to inform substitution decisions.

13. Identify the correct action: Rx for Brand X, only B-rated generics exist in the Orange Book.

    Do not substitute; dispense brand or obtain prescriber authorization. B-rated generics lack therapeutic equivalence, so substitution is prohibited without prescriber consent to ensure efficacy.

14. What is the federal reference used to determine therapeutic equivalence for generic substitution?

    FDA Orange Book therapeutic equivalence evaluations. The FDA's Orange Book lists approved drugs with therapeutic equivalence codes to guide pharmacists on safe generic substitutions under federal standards.

15. Which option correctly states whether a pharmacist may change dosage form (tablet to capsule) under generic substitution?

    No; dosage form must match unless prescriber authorizes the change. Generic substitution demands pharmaceutical equivalence, including identical dosage forms, to ensure bioequivalence without prescriber input.

16. What is the legal distinction between a "biosimilar" and an "interchangeable" biosimilar?

    Only "interchangeable" may be substituted without prescriber approval. Biosimilars lack automatic substitutability, unlike interchangeables, which meet additional FDA standards for pharmacy-level switching without approval.

17. Identify the correct action: Rx for Brand X, generic is A-rated, but patient refuses substitution.

    Dispense brand if patient requests; apply state rules for consent/charges. Patient refusal overrides substitution, requiring brand dispensing while adhering to state mandates on consent and potential cost differences.

18. What does an Orange Book "AB" rating mean for brand-to-generic substitution?

    Bioequivalent; therapeutically equivalent to the RLD. AB rating signifies demonstrated bioequivalence to the reference listed drug, ensuring comparable clinical effects for safe substitution.

19. What is the most accurate meaning of "therapeutic interchange" in dispensing decisions?

    Substitution with a different drug; requires prescriber authorization. Therapeutic interchange involves switching to a non-identical but therapeutically similar drug, necessitating prescriber consent to avoid liability.

20. Identify the correct action: Rx for reference biologic; an FDA-interchangeable biosimilar is available.

    Substitute only if state biosimilar substitution requirements are met. Interchangeable biosimilars allow substitution, but state laws may impose additional requirements like notification or documentation.

21. Identify the key Orange Book requirement before a pharmacist may substitute a generic for a brand.

    Same active ingredient, strength, dosage form, and route; A-rated. Substitution requires pharmaceutical equivalence and an A-rating to guarantee bioequivalence and therapeutic similarity per FDA guidelines.

22. Identify whether substituting levothyroxine products should be treated as routine substitution.

    Not routine; use caution and follow state policy and prescriber intent. Levothyroxine is often classified as NTI, requiring non-routine handling to maintain consistent bioavailability and therapeutic levels.

23. Identify whether changing from an IR product to an ER product is generic substitution or therapeutic interchange.

    Therapeutic interchange; requires prescriber authorization. Switching release mechanisms alters drug kinetics, classifying it as therapeutic interchange needing prescriber approval for safety.

24. What does FDA "interchangeable" mean for a biosimilar at the pharmacy level?

    May be substituted for the reference product, subject to state law. Interchangeable status allows pharmacist substitution for the reference biologic without prescriber intervention, per FDA criteria and state regulations.

25. Identify the typical labeling requirement after generic substitution when allowed by state law.

    Label must show generic name and/or manufacturer as required by state. State-specific labeling rules require displaying the actual dispensed product's details to promote accuracy and patient awareness.

Study these flashcards